| CEO Name | David J. Endicott |
| Nationality | United States |
| Net Worth Estimation | $40 million |
David J. Endicott's estimated net worth of around $40 million is primarily derived from his roles as CEO and executive at Alcon Inc., as well as accumulated stock awards, salary, performance bonuses, and previous executive positions in major pharmaceutical companies. His financial assets are further supported by years of tenure in high-ranking leadership, strategic corporate growth, and equity holdings in Alcon.
David J. Endicott, CEO of Alcon Inc., has an estimated net worth of $40 million, which is 50% of the maximum and 300% of the minimum CEO net worth recorded in the healthcare business category. His wealth is positioned in the mid-range relative to peers with estimated net worths between $10 million and $90 million.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
David J. Endicott Performance in Alcon Inc.
David J. Endicott, as CEO of Alcon Inc., demonstrated strategic leadership by driving innovation in ophthalmic surgical products and expanding global market reach. His decision-making emphasized operational efficiency and investment in R&D, enhancing Alcon's competitive position. Under Endicott's tenure, the company achieved significant revenue growth and strengthened its reputation as a leader in eye care technology.
Latest News
Alcon Inc. Reports Growth and Plans Major Acquisition Under CEO David Endicott
Alcon announced a 4% sales increase in Q2 2025 to $2.6 billion and detailed its $1.5 billion acquisition of STAAR Surgical to expand its eye care surgical offerings. CEO David J. Endicott highlighted new product successes and the strategic importance of the acquisition for addressing global myopia, with the deal expected to close within 6-12 months pending approvals. The purchase aims to enhance treatment options across the myopia spectrum and reinforce Alcon's market position.
Source: http://investor.alcon.com/news-and-events/press-releases/news-details/2025/Alcon-Reports-Second-Quarter-2025-Results-Launched-Tryptyr-and-Announced-Acquisition-of-STAAR-Surgical/default.aspx